Oncotarget

Case Reports:

Immunotherapy in mucosal melanoma: a case report and review of the literature

Hana Studentova _, Hana Kalabova, Pavel Koranda, Karin Chytilova, Ladislava Kucerova, Bohuslav Melichar and David Vrana

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:17971-17977. https://doi.org/10.18632/oncotarget.24727

Metrics: PDF 1302 views  |   HTML 2931 views  |   ?  


Abstract

Hana Studentova1, Hana Kalabova1, Pavel Koranda2, Karin Chytilova3, Ladislava Kucerova4, Bohuslav Melichar1,5 and David Vrana1

1Department of Oncology, Palacký University, Faculty of Medicine and Dentistry and University Hospital, Olomouc, Czech Republic

2Department of Nuclear Medicine, Palacký University, Faculty of Medicine and Dentistry and University Hospital, Olomouc, Czech Republic

3Department of Maxillofacial Surgery, Palacký University, Faculty of Medicine and Dentistry and University Hospital, Olomouc, Czech Republic

4Department of Pathology, Palacký University, Faculty of Medicine and Dentistry and University Hospital, Olomouc, Czech Republic

5Institute of Molecular and Translational Medicine, Palacký University, Faculty of Medicine and Dentistry and University Hospital, Olomouc, Czech Republic

Correspondence to:

Hana Studentova, email: [email protected]

Keywords: mucosal melanoma; head and neck; immunotherapy; ipilimumab; late response

Received: February 06, 2018     Accepted: February 24, 2018     Published: April 03, 2018

ABSTRACT

Background: Mucosal melanoma is a rare form of melanoma presenting variably as sores or unexplained bleeding located mainly in the head and neck region, anorectal region or female genital tract. Mucosal melanoma is usually diagnosed at an advanced stage and is characterized by an aggressive behavior. Surgery represents the mainstay of treatment for early stage melanomas, but for advanced disease there have been until recently very limited treatment options. Ipilimumab, a human monoclonal antibody directed against the cytotoxic T lymphocyte antigen 4, was the first treatment modality to demonstrate survival benefit in advanced malignant melanoma.

Method: Description of a new case and review of the literature.

Results: We present here a patient with mucosal melanoma with aggressive biological behavior and documented late response to ipilimumab.

Conclusions: Ipilimumab represents an effective treatment option in selected patients with mucosal melanoma.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24727